StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

Stock analysts at StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOLASE Price Performance

BIOL opened at $0.01 on Friday. The stock has a market cap of $330,729.30, a P/E ratio of 0.00 and a beta of 0.67. The stock’s 50 day simple moving average is $0.01 and its 200 day simple moving average is $0.02. BIOLASE has a 1-year low of $0.02 and a 1-year high of $1.94.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.